855182--5/28/2008--IBIS_TECHNOLOGY

related topics

{stock, price, share}

{product, candidate, development}

{customer, product, revenue}

{stock, price, operating}

{acquisition, growth, future}

{control, financial, internal}

{product, market, service}

{regulation, change, law}

{property, intellectual, protect}

{personnel, key, retain}

{provision, law, control}

{financial, litigation, operation}

{interest, director, officer}

{cost, regulation, environmental}

{cost, operation, labor}

Our Registered Public Acoounting Firm Has Expressed Substantial Doubt About Our Ability to Continue as a Going Concern. Our Efforts to Identify, Evaluate and Consummate a Transaction or Other Initiative to Increase the Value of the Company for our Stockholders May Not Be Successful. Should We Consummate a Strategic Transaction or Other Strategic Alternative, There is No Guarantee that Our Stockholders will Realize Greater Value For, or Preserve Existing Value of, Their Shares of the Company. We Have Received Only Limited Orders for Our Oxygen Implanter Equipment. If We Are Unable to Secure Additional Orders Within a Reasonable Timeframe in the Future, or Otherwise Obtain Offsetting Revenue, We may Be Unable to Continue to Conduct Operations in a Manner Consistent with Our Current Plan. The Commercial Market for SIMOX-SOI Technology is Still Developing and May Never Fully Develop. We Have Relied Heavily on Sales to One Customer. We Expect to Rely on Sales to a Limited Number of Customers Which May Cause Sales to Vary Significantly from Quarter to Quarter Causing Our Operating Results to Fluctuate We May Need Substantial Additional Capital to Continue Operations in the Future. The Company Received Notice from the Nasdaq Stock Market that at April 16, 2008 Nasdaq had not received the Company s Form 10-K for the fiscal year ended December 31, 2007, as required by Marketplace Rule 4310(c)(14). The Company Received Notice from the Nasdaq Stock Market that its Bid Price is Below the Minimum Share Price Requirement. The issuance of shares in connection with the February 2007 financing and the exercise of the related warrants will dilute the value of our shares of common stock and could cause the price of our shares of common stock to decline. We Have Significant Losses and May Never Be Able to Sustain Profitability. Revenue Recognition and Cash Payments from Customers Depend on a Manufacturing and Customer Qualification and Acceptance Process that is Complex, Lengthy and Costly. We Expect Our Quarterly Revenue and Operating Results to Fluctuate Significantly. Competitors and Competing Technologies May Render Some or All of Our Products or Future Products Noncompetitive or Obsolete Which Would Result in a Write-down for Impaired or Obsolete Assets. We Must Continually Improve Existing Products, Design and Sell New Products and Manage the Costs of Research and Development in Order to Compete Effectively. The Sales Cycle for Our Oxygen Implanter Equipment is Lengthy and Complex and Certain Third Party Licensing Agreements May Cause Significant Delays. Our Implanters and Associated Technology are Subject to Export Regulations, Which Could Prevent or Delay the Sale of Such Products in Foreign Countries. The Loss of Key Members of Our Scientific and Management Staff Could Delay and May Prevent the Achievement of Our Research, Development and Business Objectives. Changes in Accounting Standards Regarding Stock Option Plans Could Limit the Desirability of Granting Stock Options, Which Could Harm Our Ability to Attract and Retain Employees, and Have Also Negatively Impacted Our Results of Operations. We May Not Be Able to Successfully Produce Our Products on a Large-Scale. Our Latest Products Have Not Been Used in Large-Scale Long-Term Production and Consequently They May Not Be Able to Perform at the Availability Levels Expected for Continuous (7 Days per Week / 24 Hours per Day) Operation. (and May Be Subject to Unknown and Undetected Hardware or Software Failures). We May Not Be Able to Use All of Our Existing or Future Manufacturing Capacity at a Profitable Level. We May Not Successfully Form or Maintain Desirable Strategic Alliances. We May Have Difficulty Obtaining the Materials and Components Needed to Produce Our Products, and At Least One Major Component Has Only One Source. We May Not Be Able to Protect Our Patents and Proprietary Technology. If We Do Not Comply With All Applicable Environmental Regulations, We May be Subject to Fines and Other Sanctions. Our Stock Price is Highly Volatile. Concentrated Ownership of Shares by One Shareholder and Its Affiliates Could Affect the Price of Our Common Stock. Future Issuances of Preferred Stock May Diminish the Rights of Our Common Stockholders. Anti-takeover Provisions in Our Charter and Bylaws and Provisions of Massachusetts Law Could Make an Acquisition of the Business by a Third-Party Difficult. Limitations on Effectiveness of Controls. If We Fail to Maintain an Effective System of Internal Control over Financial Reporting and Disclosure Controls and Procedures, We May Be Unable to Accurately Report our Financial Results and Comply with the Reporting Requirements Under the Exchange Act. Evolving Regulation of Corporate Governance and Public Disclosure May Result in Additional Expenses and Continuing Uncertainty.

Full 10-K form ▸

855182--5/28/2008--IBIS_TECHNOLOGY_CORP